Clinical trialsCompany release

Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial

Can-Fite BioPharma Ltd. (CANF) · Wed 18 Nov 2026

The last of the first 247 patients in the pivotal oral piclidenoson study has received the final dose, with an independent committee due to review interim data in Q1 2027.

Can-Fite BioPharma said on 18 November 2026 that dosing is complete for the interim-analysis cohort in its pivotal Phase III study of oral piclidenoson in moderate-to-severe plaque psoriasis. The last of the first 247 patients has received the final dose.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Can-Fite BioPharma Ltd. ↗

Article written by VigiEye from the official source (Can-Fite BioPharma Ltd.). Claims are the company's own. AI-assisted; check the source before acting.